BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

815 related articles for article (PubMed ID: 24193289)

  • 1. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Chua TC; Moran BJ; Sugarbaker PH; Levine EA; Glehen O; Gilly FN; Baratti D; Deraco M; Elias D; Sardi A; Liauw W; Yan TD; Barrios P; Gómez Portilla A; de Hingh IH; Ceelen WP; Pelz JO; Piso P; González-Moreno S; Van Der Speeten K; Morris DL
    J Clin Oncol; 2012 Jul; 30(20):2449-56. PubMed ID: 22614976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
    Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
    In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
    Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
    In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
    Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
    Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative outcomes of laparoscopic vs open cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for treatment of peritoneal surface malignancies.
    Passot G; Bakrin N; Isaac S; Decullier E; Gilly FN; Glehen O; Cotte E
    Eur J Surg Oncol; 2014 Aug; 40(8):957-62. PubMed ID: 24209429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center.
    Deraco M; Kusamura S; Laterza B; Favaro M; Fumagalli L; Costanzo P; Baratti D
    In Vivo; 2006; 20(6A):773-6. PubMed ID: 17203766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iterative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results.
    Golse N; Bakrin N; Passot G; Mohamed F; Vaudoyer D; Gilly FN; Glehen O; Cotte E
    J Surg Oncol; 2012 Aug; 106(2):197-203. PubMed ID: 22331814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and HIPEC: preliminary results in highly selected patients.
    Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2013 Dec; 68(6):551-8. PubMed ID: 24193287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.
    Cioppa T; Vaira M; Bing C; D'Amico S; Bruscino A; De Simone M
    World J Gastroenterol; 2008 Nov; 14(44):6817-23. PubMed ID: 19058307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis.
    Marcotte E; Dubé P; Drolet P; Mitchell A; Frenette S; Leblanc G; Leclerc YE; Sideris L
    World J Surg Oncol; 2014 Nov; 12():332. PubMed ID: 25380618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
    Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete cytoreduction for pseudomyxoma peritonei is optimal but maximal tumor debulking may be beneficial in patients in whom complete tumor removal cannot be achieved.
    Dayal S; Taflampas P; Riss S; Chandrakumaran K; Cecil TD; Mohamed F; Moran BJ
    Dis Colon Rectum; 2013 Dec; 56(12):1366-72. PubMed ID: 24201390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
    Chua TC; Yan TD; Smigielski ME; Zhu KJ; Ng KM; Zhao J; Morris DL
    Ann Surg Oncol; 2009 Jul; 16(7):1903-11. PubMed ID: 19387742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome.
    Sugarbaker PH
    Eur J Surg Oncol; 2001 Apr; 27(3):239-43. PubMed ID: 11373099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with pseudomyxoma peritonei.
    Deraco M; De Simone M; Rossi CR; Cavaliere F; Di Filippo F; Vaira M; Piatti P; Kusamura S
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):35-9. PubMed ID: 16767904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.